Replication-competent, oncolytic herpes simplex virus type 1 mutants induce a bystander effect following ganciclovir treatment

被引:13
|
作者
Luo, Chenhong
Mori, Isamu
Goshima, Fumi
Ushijima, Yoko
Nawa, Akihiro
Kimura, Hiroshi
Nishiyama, Yukihiro [1 ]
机构
[1] Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4668550, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Obstet & Gynecol, Nagoya, Aichi 4668550, Japan
[3] Aichi Med Univ, Sch Med, Dept Immunol & Microbiol, Aichi 4801195, Japan
来源
JOURNAL OF GENE MEDICINE | 2007年 / 9卷 / 10期
关键词
herpes simplex virus; thymidine kinase; ganciclovir; cancer; bystander effect; apoptosis; connexin; gap junction;
D O I
10.1002/jgm.1085
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Cells expressing herpes simplex virus (HSV) thymidine kinase (tk) are killed by ganciclovir (GCV). Adjacent cells without HSV-tk also die, a phenomenon known as the 'bystander effect'. However, there is no evidence that replicationcompetent HSV induces a bystander effect in the presence of GCV. Therefore, we investigated the bystander effect in HEp-2 cells infected with replicationcompetent, oncolytic HSV-1 mutants, hrR3 and HF10. In cells infected at a multiplicity of infection (MOI) of 3, GCV did not induce apoptosis. At low MIS of 0.3 and 0.03, however, a number of adjacent, uninfected cells apoptosed following GCV treatment. Irrespective of GCV treatment, HEp2 cells expressed minimal levels of connexin 43 (Cx43). However, Cx43 expression was enhanced by GCV in response to infection with HF10 at an MOI of 0.3, but not at an MOI of 3. Expression of other proteins involved in gap junctions, including Cx26 and Cx40, was not augmented under these conditions. The PKA and PI3K signal transduction pathways are likely involved in enhanced Cx43 expression as inhibitors of these pathways prevented Cx43 upregulation. These results suggest that infection with replication-competent HSV-1 induces the bystander effect in cells treated with GCV because of efficient intercellular transport of active GCV through abundant gap junctions. Copyright (C) 2 007 John Wiley & Sons, Ltd.
引用
收藏
页码:875 / 883
页数:9
相关论文
共 50 条
  • [31] Phase I Trial of Intratumoral (IT) Administration of HF10, a Replication-Competent Herpes Simplex Virus Type 1, in Patients with Refractory Superficial Cancer
    Ferris, Robert L.
    Nemunaitis, John
    Argiris, Athanassios
    Gross, Neil
    Smith, Russell
    Senzer, Neil
    Bedell, Cynthia
    Ungerleider, Richard S.
    Tanaka, Maki
    Nishiyama, Yukihiro
    MOLECULAR THERAPY, 2012, 20 : S83 - S83
  • [32] Replication-competent Herpes Simplex Virus Retargeted to HER2 as Therapy for High-grade Glioma
    Gambini, Eleonora
    Reisoli, Elisa
    Appolloni, Irene
    Gatta, Valentina
    Campadelli-Fiume, Gabriella
    Menotti, Laura
    Malatesta, Paolo
    MOLECULAR THERAPY, 2012, 20 (05) : 994 - 1001
  • [33] Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus
    Todo, T
    Rabkin, SD
    Sundaresan, P
    Wu, AG
    Meehan, KR
    Herscowitz, HB
    Martuza, RL
    HUMAN GENE THERAPY, 1999, 10 (17) : 2741 - 2755
  • [34] The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1
    Kalke, Kiira
    Orpana, Julius
    Lasanen, Tuomas
    Esparta, Olaya
    Lund, Liisa M.
    Frejborg, Fanny
    Vuorinen, Tytti
    Paavilainen, Henrik
    Hukkanen, Veijo
    VIRUSES-BASEL, 2022, 14 (06):
  • [35] Attenuated Replication-Competent Herpes Simplex Virus Expressing an ECM-Modifying Transgene Hyaluronan Synthase 2 of Naked Mole Rat in Oncolytic Gene Therapy
    Palomaeki, Jussi
    Kalke, Kiira
    Orpana, Julius
    Lund, Liisa
    Frejborg, Fanny
    Paavilainen, Henrik
    Jaervelaeinen, Hannu
    Hukkanen, Veijo
    MICROORGANISMS, 2023, 11 (11)
  • [36] Characterization of Herpes Simplex Virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity
    Kokoris, MS
    Black, ME
    PROTEIN SCIENCE, 2002, 11 (09) : 2267 - 2272
  • [37] Oncolytic herpes simplex virus type 1 and host immune responses
    Fukuhara, Hiroshi
    Todo, Tomoki
    CURRENT CANCER DRUG TARGETS, 2007, 7 (02) : 149 - 155
  • [38] Inhibition of rat vascular smooth muscle cell proliferation in vitro and in vivo by recombinant replication-competent herpes simplex virus
    Miyatake, SI
    Yukawa, H
    Toda, H
    Matsuoka, N
    Takahashi, R
    Hashimoto, N
    STROKE, 1999, 30 (11) : 2431 - 2438
  • [40] Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment
    Mi, Yan-Xia
    Long, Ya-Hong
    Li, Yun-Chun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (09) : 1321 - 1325